Oryzon Genomics Eulerpool News

Oryzon Genomics Eulerpool News

Oryzon Genomics Stock News

Oryzon Genomics is being monitored by journalists and investors worldwide. We gather the latest Oryzon Genomics news here.

• September 11 ·

  Yahoo
  ORYZON Receives “Intention to Grant” Communication for Patent Relating to the Use of Vafidemstat in Borderline Personality Disorder
• September 9 ·

  Yahoo
  ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in First-Line Acute Myeloid Leukemia
• September 3 ·

  Yahoo
  ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat with Additional “Decision to Grant” Communications
• August 29 ·

  Yahoo
  ORYZON to Provide Corporate Progress Updates at Several Events in September
• July 31 ·

  Yahoo
  ORYZON reports financial results and corporate update for half-year ending June 30, 2024
• July 8 ·

  Yahoo
  ORYZON Receives “Decision to grant” for Two Important Patents for Vafidemstat in Japan
• June 28 ·

  Yahoo
  ORYZON Announces Voting Results from its 2024 Annual General Meeting of Shareholders
• June 26 ·

  Yahoo
  ORYZON Announces Presentation of Final Data From PORTICO, Vafidemstat’s Global Phase IIb Trial in Borderline Personality Disorder, at the 37th ECNP Annual Conference
• June 14 ·

  Yahoo
  ORYZON Presents Preliminary Data From Ongoing Phase Ib FRIDA Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory FLT3-mut AML Patients at EHA-2024
• June 3 ·

  Yahoo
  ORYZON Announces Journal Publication of Final Phase IIa ALICE Results with Iadademstat in The Lancet Hematology